Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Wang, Yonggang ^a,b,d   Shek, Felix H ^b   Wong, Kwong F ^c   Liu, Ling Xiao ^d   Zhang, Xiao Qian ^e   Yuan, Yi ^c   Khin, Ester ^c   Hu, Mei Yu ^a   Wang, Jian Hua ^d   Poon, Ronnie T P ^b   Hong, Wanjin ^e   Lee, Nikki P ^b   Luk, John M ^b,c,e  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d FUDAN UNIVERSITY   (China)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CADHERIN; CADHERIN 17; CADHERIN 17 ANTIBODY; CASPASE 8; CASPASE 9; CISPLATIN; LIC5 ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; WNT PROTEIN; CASP8 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CDH17 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BETA CATENIN SIGNALING; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CARCINOGENICITY; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS TISSUE TUMOR; SYNAPTIC TRANSMISSION; TUMOR XENOGRAFT; WESTERN BLOTTING; WNT SIGNALING; ANIMAL; BAGG ALBINO MOUSE; CARCINOGENESIS; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; LIVER TUMOR; METABOLISM; TUMOR CELL LINE; TUMOR VOLUME; WNT SIGNALING PATHWAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BETA CATENIN; CADHERINS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; TUMOR BURDEN; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902030237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072386     Document Type: Article

References (43)

1. Berx G, van Roy F (2009) Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 1: a003129.
2. Makrilia N, Kollias A, Manolopoulos L, Syrigos K (2009) Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest 27: 1023-1037.
3. Blaschuk OW, Devemy E (2009) Cadherins as novel targets for anti-cancer therapy. Eur J Pharmacol 625: 195-198.
4. Fatima S, Lee NP, Luk JM (2011) Dickkopfs and Wnt/beta-catenin signalling in liver cancer. World J Clin Oncol 2: 311-325.
5. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, et al. (2012) Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. J Surg Res 174: 120-129.
6. Endo K, Ueda T, Ueyama J, Ohta T, Terada T (2000) Immunoreactive Ecadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 31: 558-565.
7. Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, et al. (2011) Loss of Ecadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol 24: 1237-1247.
8. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, et al. (2007) Pcadherin expression in breast cancer: a review. Breast Cancer Res 9: 214.
9. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2007) A switch from Ecadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13: 7003-7011.
10. Gessner R, Tauber R (2000) Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci 915: 136-143.
11. Lee NP, Poon RT, Shek FH, Ng IO, Luk JM (2010) Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta 1806: 138-145.
12. Wendeler MW, Jung R, Himmelbauer H, Gessner R (2006) Unique gene structure and paralogy define the 7D-cadherin family. Cell Mol Life Sci 63: 1564-1573.
13. Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, et al. (1994) Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science 264: 430-433.
14. Qiu HB, Zhang LY, Ren C, Zeng ZL, Wu WJ, et al. (2013) Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/betacatenin signaling. PloS one 8: e56959.
15. Liu LX, Lee NP, Chan VW, Xue W, Zender L, et al. (2009) Targeting cadherin- 17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 50: 1453-1463.
16. Ding ZB, Shi YH, Zhou J, Shi GM, Ke AW, et al. (2009) Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B viruspositive hepatocellular carcinoma. Cancer 115: 4753-4765.
17. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, et al. (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116: 1582-1595.
18. Wang XQ, Luk JM, Leung PP, Wong BW, Stanbridge EJ, et al. (2005) Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res 11: 483-489.
19. Wang XQ, Luk JM, Garcia-Barcelo M, Miao X, Leung PP, et al. (2006) Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin Cancer Res 12: 5248-5252.
20. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, et al. (2003) Identification of liverintestine cadherin in hepatocellular carcinoma-a potential disease marker. Biochem Biophys Res Commun 311: 618-624.
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
22. Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, et al. (2011) AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 30: 1229-1240.
23. Lee NP, Leung KW, Wo JY, Tam PC, Yeung WS, et al. (2006) Blockage of testicular connexins induced apoptosis in rat seminiferous epithelium. Apoptosis 11: 1215-1229.
24. Luk JM, Su YC, Lam SC, Lee CK, Hu MY, et al. (2005) Proteomic identification of Ku70/Ku80 autoantigen recognized by monoclonal antibody against hepatocellular carcinoma. Proteomics 5: 1980-1986.
25. Lee NP, Leung KW, Cheung N, Lam BY, Xu MZ, et al. (2008) Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics 8: 2136-2149.
26. Lee NP, Tsang FH, Shek FH, Mao M, Dai H, et al. (2010) Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer 127: 968-976.
27. Lee NP, Chen L, Lin MC, Tsang FH, Yeung C, et al. (2009) Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res 8: 1293-1303.
28. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y (2009) Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 18: 81-100.
29. Belda-Iniesta C, Ibanez de Caceres I, de Castro J (2011) Monoclonal antibodies for medical oncology: a few critical perspectives. Clin Transl Oncol 13: 84-87.
30. Damasceno M (2011) Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer. Curr Opin Oncol 23 Suppl: S3-9.
31. Callahan R, Hurvitz S (2011) Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol 23: 37-43.
32. Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, et al. (2011) Targeted therapy in colorectal cancer: current status and future challenges. Curr Med Chem 18: 1599-1612.
33. Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV (2005) Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 17: 212-217.
34. Zhu R, Wong KF, Lee NP, Lee KF, Luk JM (2010) HNF1α and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem 111: 618-626.
35. Jung R, Wendeler MW, Danevad M, Himmelbauer H, Gessner R (2004) Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis. Cell Mol Life Sci 61: 1157-1166.
36. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, et al. (2010) Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16: 1414-1420.
37. Spratlin J (2011) Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 13: 97-102.
38. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, et al. (2010) Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 36 Suppl 3: S11-15.
39. Driscoll JJ, Dechowdhury R (2010) Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy. Target Oncol 5: 281-289.
40. De Smaele E, Ferretti E, Gulino A (2010) Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 11: 707-718.
41. Villanueva A, Llovet JM (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology 140: 1410-1426.
42. Luk JM, Wong KF (2006) Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma. Clin Exp Pharmacol Physiol 33: 482-488.
43. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, et al. (2011) Engineering the variable region of therapeutic IgG antibodies. MAbs 3: 243-252.